Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SSTR2”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Testing effectiveness (Phase 2)Study completedNCT02936323
What this trial is testing

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Who this might be right for
Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma
Tarveda Therapeutics 89
Testing effectiveness (Phase 2)Study completedNCT05410743
What this trial is testing

Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors

Who this might be right for
SSTR2-positive Tumors
The First Affiliated Hospital of Xiamen University 30
Very early researchLooking for participantsNCT06632860
What this trial is testing

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Who this might be right for
Iodine-resistant Thyroid CancerMeningiomaNETs
Peking Union Medical College Hospital 40
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Testing effectiveness (Phase 2)Looking for participantsNCT07284589
What this trial is testing

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Who this might be right for
Healthy (Controls)Healthy VolunteersNeuroendocrine (NE) Tumors
Akiva Mintz 200
Testing effectiveness (Phase 2)Ended earlyNCT03773133
What this trial is testing

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

Who this might be right for
Small Cell Lung Cancer and Breast Cancer
Ipsen 9
Testing effectiveness (Phase 2)Ended earlyNCT06939036
What this trial is testing

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Who this might be right for
Small Cell Lung Cancer Extensive StageMerkel Cell Carcinoma
Ariceum Therapeutics GmbH 2
Early research (Phase 1)Active Not RecruitingNCT06379217
What this trial is testing

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Who this might be right for
Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals 31
Very early researchStudy completedNCT05871320
What this trial is testing

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine Tumors
Jagiellonian University 10
Very early researchLooking for participantsNCT06632873
What this trial is testing

177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

Who this might be right for
SSTR2 and Integrin αVβ3 Positive Tumors
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT06982300
What this trial is testing

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Who this might be right for
Nasopharyngeal Carcinoma (NPC)
University Medical Center Groningen 10
Testing effectiveness (Phase 2)Looking for participantsNCT06955169
What this trial is testing

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Who this might be right for
Intracranial Meningioma
RTOG Foundation, Inc. 153
Not applicableLooking for participantsNCT05873777
What this trial is testing

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Who this might be right for
SSTR2FAPPositron-Emission Tomography
The First Affiliated Hospital of Xiamen University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04298541
What this trial is testing

Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

Who this might be right for
Meningioma
Weill Medical College of Cornell University 6
Very early researchUnknownNCT02817945
What this trial is testing

Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

Who this might be right for
Lung CancerNeuroendocrine Neoplasm
Peking Union Medical College Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06456359
What this trial is testing

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Who this might be right for
Desmoplastic Small Round Cell TumorSynovial Sarcoma
University Hospital Heidelberg 28
Very early researchLooking for participantsNCT07301801
What this trial is testing

Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors

Who this might be right for
Malignant TumorsSSTR2PET
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+3 more
Perspective Therapeutics 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT03454763
What this trial is testing

Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

Who this might be right for
Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 618
Load More Results